Next Generation Sequencing Market Size, Share, Opportunities, And Trends By Product and Services (Sequencing Systems, Consumables, Software, Sequencing Services and Analysis), By Technology (Sequencing by Synthesis, ION Torrent Sequencing, Nanopore Sequencing, Others), By Application (Agriculture and Animal Research, Biomarker Discovery, Drug Discovery, Diagnostics, Precision Medicine), And By Geography - Forecasts From 2025 To 2030

  • Published : Nov 2024
  • Report Code : KSI061610956
  • Pages : 165
excel pdf power-point

The next generation sequencing market is projected to grow at a CAGR of 14.25% between 2025 to 2030.

Next-generation sequencing (NGS) has been a parallel sequencing technology that provides scalability, speed, and ultra-high throughput. The technology is then used to find the order of nucleotides in entire or complete genomes or various targeted areas and regions of RNA or DNA. NGS has modernized and advanced the biological sciences, enabling labs to perform a wide variety of applications and study biological systems at various levels.

Today's difficult and advanced genomics questions demand information that exceeds the capacity of traditional and commonly used DNA sequencing technologies. NGS has filled that gap and has become an everyday tool to address these questions. It allows labs to Rapidly sequence whole genomes, deeply sequence target regions, utilize RNA sequencing (RNA-Seq) to discover novel RNA variants and splice sites, or quantify mRNAs for gene expression analysis and has many other advantages over the old traditional methods.

Driving Factors

The worldwide demand for next-generation sequencing (NGS) services and products is highly driven by a surge in the application of NGS, an increase in genome mapping programs, and a surge in collaborations, technological advancement in NGS technology, and various partnerships that result in significant investments in R&D in NGS technology. The continuous technological advancements in the industry have led to the introduction of efficient, portable, and easy-to-use NGS platforms, capable of providing rapid and accurate results which have led to the overall growth in the industry. Such developments in the industry provide many new entrants in the industry and also give a competitive edge to the prominent companies in the industry an edge over each other which leads to more research and development programs in the industry. It is also driven by an increase in genome mapping programs; a rise in applications of next-generation sequencing; an increase in healthcare expenditure; and technological advancements in sequencing platforms. Moreover, with the arrival of the COVID-19 virus, the application of NGS has proven to be quite effective in knowing the speed with which the virus spreads and knowing the genetic sequence of the virus and it further leads to technological advancements in those areas.

Growth Factors

  • Support from the government and private sectors

A lot of developing countries have invested in their research and development sectors and in sequencing programs to get a deep knowledge of genetics and diseases. Many such government organizations have taken an active part in the sequencing program to find better ways for the treatment of cancer and other diseases. Due to this large support, several new entrants have entered the market as many sequencing projects have been introduced which leads to the overall growth of this industry and gives growth opportunities to key players in the industry. Such type of growth has provided the wide-scale use of consumables required and the adoption of NSG instruments.

Restraints

  • Lack of skill power and expenditure on Research and Development Programs

The expenditure on research and development in growing economies is mainly dependent on funding provided by external sources. Although governments and private bodies try to provide funds for the research programs, many research firms and academic institutes are facing budget problems and are not able to afford advanced and premium-priced equipment and technologies which further leads to an effect on the growth of these industries and their expansion in developing nations. Also, the lack of skilled professionals in this industry is less in number which further hinders the growth of this industry. Due to this, the interpretation of complex data takes time and researchers face difficulties leading to slow growth in the industry.

Impact of COVID-19 on the next-generation sequencing market

The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. It has caused a highly transmissible and ongoing pandemic worldwide. With the growth of its development, next-generation sequencing plays imperative roles in many aspects. Several pharmaceutical companies and agencies have contributed their bit to curb the effect of the virus, from manufacturing PPE kits to developing test kits to detect the virus and vaccines to reduce transmission. Companies have increased their R&D and manpower in manufacturing products to curb the virus. The overall impact on the next-generation sequencing industry and the market is projected to be positive owing to the increasing advantage of determining and finding the genetic sequence of a virus, which allows scientists to understand the overall mutation of the virus. Furthermore, genome sequencing has been used to understand the spread of COVID-19 and has the potential to understand the impact of interventions and their spread and help guide treatments in the future.

Hundreds of coronaviruses and SARS-CoV-2 genomes which were determined with NGS are publicly available for researchers to study the origin of COVID-19.

Segmentation:

  • By Products & Services
    • Sequencing Systems
    • Consumables
    • Software
    • Sequencing Services and Analysis
  • By Technology
    • Sequencing by Synthesis
    • ION Torrent Sequencing
    • Nanopore Sequencing
    • Others 
  • By Application
    • Agriculture and Animal Research
    • Biomarker Discovery
    • Drug Discovery
    • Diagnostics
    • Precision Medicine
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • UK
      • Spain
      • Others
    • Middle East and Africa
      • UAE
      • Israel
      • South Africa
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

1. INTRODUCTION

1.1. Market Overview

1.2. Covid-19 Scenario

1.3. Market Definition

1.4. Scope of The Study

1.5. Currency

1.6. Market Segmentation

1.7. Assumptions

1.8. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

2.3. Validation

3. KEY FINDINGS

4. MARKET DYNAMICS

4.1. Drivers

4.1.1. Growing Demand for NGS in Genetic Disorder Diagnostics

4.1.2. Increasing Investments and Support From Government and Private Sectors

4.2. Restraints

4.2.1. Lack of Skill and High Equipment Costs

4.2.2. Complications Associated With Big Data Management

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2.  Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. NEXT-GENERATION SEQUENCING MARKET BY PRODUCTS & SERVICES

5.1. Introduction

5.2. Sequencing Systems

5.3. Consumables

5.4. Software

5.5. Sequencing Services and Analysis

6. NEXT-GENERATION SEQUENCING MARKET BY TECHNOLOGY

6.1. Introduction

6.2. Sequencing by Synthesis

6.3. Ion Torrent Sequencing

6.4. Nanopore Sequencing

6.5. Others

7. NEXT-GENERATION SEQUENCING MARKET BY APPLICATION

7.1. Introduction

7.2. Agriculture and Animal Research

7.3. Biomarker Discovery

7.4. Drug Discovery

7.5. Diagnostics

7.6. Precision Medicine

7.7. Others

8. NEXT-GENERATION SEQUENCING MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East And Africa

8.5.1. UAE

8.5.2. Israel

8.5.3. South Africa

8.5.4. Others

8.6. Asia Pacific

8.6.1. Introduction

8.6.2. China

8.6.3. Japan

8.6.4. India

8.6.5. South Korea

8.6.6. Taiwan

8.6.7. Thailand

8.6.8. Indonesia

8.6.9. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. Company Profiles

10.1. Roche Holding Ag

10.1.1. Overview

10.1.2. Products And Services

10.1.3. Financials

10.1.4. Key Developments

10.2. Agilent Technologies Inc.

10.2.1. Overview

10.2.2. Products And Services

10.2.3. Financials

10.2.4. Key Developments

10.3. Illumina, Inc.

10.3.1. Overview

10.3.2. Products And Services

10.3.3. Financials

10.3.4. Key Developments

10.4. Thermo Fisher Scientific

10.4.1. Overview

10.4.2. Products And Services

10.4.3. Financials

10.4.4. Key Developments

10.5. Macrogen, Inc.

10.5.1. Overview

10.5.2. Products And Services

10.5.3. Financials

10.5.4. Key Developments

10.6. Beijing Genomics Institute

10.6.1. Overview

10.6.2. Products And Services

10.6.3. Key Developments

10.7. Qiagen

10.7.1. Overview

10.7.2. Products And Services

10.7.3. Financials

10.7.4. Key Developments

10.8. DNASTAR

10.8.1. Overview

10.8.2. Products And Services

10.8.3 Key Developments

10.9. Eurofins Genomics

10.9.1. Overview

10.9.2. Products And Services

10.9.3. Financials

10.9.4. Key Developments

10.10. Pacific Biosciences of California, Inc.

10.10.1. Overview

10.10.2. Products And Services

10.10.3. Financials

10.10.4. Key Developments

LIST OF TABLES

LIST OF FIGURES

   Roche Holding AG

   Agilent Technologies

   Illumina, Inc.

   Thermo Fisher Scientific.

   Macrogen, Inc

   Beijing Genomics Institute

   Qiagen

  .DNASTAR

   GATC Biotech AG

   Pacific Biosciences of California, Inc.